Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04260152 · ClinicalTrials.gov registry record · NA

Evaluation of Geistlich Fibro-Gide® + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months

A NA study of Gingival Recession, sponsored by Geistlich Pharma.

Completed
Registry status
NA
Development phase
30
Enrollment target
3
Study locations

NCT04260152 is a NA study of Gingival Recession that has completed, run by Geistlich Pharma. The registered enrollment target is 30 participants, roughly in line with the 31-participant average among 10 other Gingival Recession trials with a reported enrollment target. The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04260152, a NA study of Gingival Recession, has completed, sponsored by Geistlich Pharma.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
3
Study locations

Study Summary

This double blind, randomized, split mouth study evaluates the non-inferiority of Geistlich Fibro-Gide® in comparison to connective tissue graft for the treatment of Miller Class I or II recession defects at 6 months post treatment.

Conditions Studied

Interventions

  • DEVICE Geistlich Fibro-Gide
  • PROCEDURE Connective Tissue Graft (CTG

Study Locations (3)

Michigan

  • Seven Lakes Periodontitis - Fenton

Texas

  • Perio Health Professionals - Houston

Washington

  • Oral Health Specialists - Tacoma

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2018-09-01
Est. Completion 2020-07-22
Phase NA

Sponsor

Geistlich Pharma

5 total trials

What the Registry Record Tells You About NCT04260152

The ClinicalTrials.gov registry entry for NCT04260152 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 31-participant average among 10 other Gingival Recession trials with a reported enrollment target. The listed sponsor is Geistlich Pharma, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gingival Recession appearing as the primary indexed condition, and to 2 interventions - of which Geistlich Fibro-Gide is the first listed.

NCT04260152 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Michigan, Texas, Washington.

Frequently Asked Questions

What is clinical trial NCT04260152 about?

NCT04260152 is a clinical study titled "Evaluation of Geistlich Fibro-Gide® + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months". This double blind, randomized, split mouth study evaluates the non-inferiority of Geistlich Fibro-Gide® in comparison to connective tissue graft for the treatment of Miller Class I or II recession defects at 6 months post treatment.

What is the current status of trial NCT04260152?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2018-09-01. Estimated completion is 2020-07-22.

What conditions does trial NCT04260152 study?

This clinical trial studies the following conditions: Gingival Recession.

What interventions are being tested in trial NCT04260152?

The interventions under investigation include: Geistlich Fibro-Gide (DEVICE), Connective Tissue Graft (CTG (PROCEDURE).

Who is sponsoring clinical trial NCT04260152?

This trial is sponsored by Geistlich Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04260152 being conducted?

This trial has 3 study locations across Michigan, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gingival Recession

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.